Clinical data | |
---|---|
Trade names | Clopixol |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Oral, IM |
Drug class | Typical antipsychotic |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 49% (oral) |
Protein binding | 98% |
Metabolism | Liver (CYP2D6 and CYP3A4-mediated) |
Elimination half-life | 20 hours (oral), 19 days (IM) |
Excretion | Feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.053.398 |
Chemical and physical data | |
Formula | C22H25ClN2OS |
Molar mass | 400.97 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Zuclopenthixol (brand names Cisordinol, Clopixol and others), also known as zuclopentixol, is a medication used to treat schizophrenia and other psychoses. It is classed, pharmacologically, as a typical antipsychotic. Chemically it is a thioxanthene. It is the cis-isomer of clopenthixol (Sordinol, Ciatyl).[3] Clopenthixol was introduced in 1961, while zuclopenthixol was introduced in 1978.
Zuclopenthixol is a D1 and D2 antagonist, α1-adrenergic and 5-HT2 antagonist.[4] While it is approved for use in Australia, Canada, Ireland, India, New Zealand, Singapore, South Africa and the UK it is not approved for use in the United States.[5][6]